A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Italy- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Largo Giovanni Alessandro Brambilla 3, 50134 Florence, Italy
Azienda Ospedaliero Universitaria Careggi in Florence, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Colorectal cancer metastatic, Myelodysplastic syndrome, Myelofibrosis, and other specialisations. This site conducts important research.
At Azienda Ospedaliero Universitaria Careggi, a major share of research in oncology focuses on a wide range of solid tumors, especially breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, and renal cell carcinoma. Many studies aim to test new treatment strategies, improve outcomes after standard therapy, and better control advanced or metastatic disease.
This activity reflects a strong focus on improving cancer control, extending survival, and refining treatment choices for patients with difficult-to-treat malignancies.
The site also has extensive research in hematology, with trials covering acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, myelofibrosis, and other blood and lymphatic diseases. These studies are designed to test new therapies, improve disease control, and support patients whose cancers have returned or no longer respond well to standard care.
The breadth of this work shows a strong commitment to advancing care for both malignant and non-malignant blood disorders.
A substantial portion of research at Careggi addresses immune system diseases and chronic inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Crohn’s disease, ulcerative colitis, and asthma. The trials in this field often aim to reduce disease activity, improve daily symptoms, and evaluate whether newer immune-targeted treatments can offer better control than current care.
This therapeutic area highlights the site’s strong interest in treatments that modulate the immune system more precisely and safely.
Clinical trials at Azienda Ospedaliero Universitaria Careggi also span cardiovascular disease and kidney disease, with research in atrial fibrillation, atherosclerotic cardiovascular disease, myocardial infarction, hypertrophic cardiomyopathy, chronic kidney disease, and IgA nephropathy. These studies generally seek to improve prevention, reduce complications, and test new approaches for patients at elevated risk of heart, vessel, or renal damage.
The work combines treatment evaluation with efforts to better protect organ function and reduce long-term cardiovascular and renal events.
The site conducts notable research in neurology, eye diseases, and rare disorders, including multiple sclerosis, migraine, Alzheimer’s disease, diabetic macular edema, age-related macular degeneration, and Fabry disease. Many of these trials aim to improve symptom control, slow disease progression, or evaluate new options for conditions with limited treatment choices.
This mix of common and rare conditions shows a broad interest in both everyday neurological care and highly specialized medicine.
Beyond cancer and immune-mediated disease, the research portfolio includes digestive system diseases, metabolic disorders, and other specialized fields such as diabetes, liver disease, psoriatic disease, and sleep and behavioral conditions. These studies often focus on improving disease control, evaluating better supportive care, or clarifying how treatment affects day-to-day health.
Overall, the site supports a wide-ranging clinical research program that extends well beyond one specialty and addresses many unmet medical needs.
Clinical trials currently enrolling participants at this site.
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
ItalyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.